Expression of JL1 Is an effective adjunctive marker of leukemia cutis

Young Su Park, So Hyung Park., Seo Jeong Park., Youngji Kim., Kee Taek Jang., Young Hyeh Ko., Mi Woo Lee., Joo Ryung Huh., Chan Sik Park.

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Context.-Specific differentiation of leukemia cutis (LC) from nonleukemic dermatoses is crucial to ensure proper treatment for the disease. Because of the exceptionally variable histologic features of LC and the frequent nonleukemic dermatoses in leukemia patients, identification of leukemic cells that infiltrate skin lesions is important. Here, we introduce JL1, a novel leukemiaassociated surface antigen, which is not expressed in mature human tissue but in cortical thymocytes and small subpopulations of bone marrow hematopoietic precursors. Objectives.-To assess the expression pattern of JL1 in LC and compare it with other commonly used markers. Also, to evaluate the expression of JL1 in other cutaneous lesions that need differential diagnoses. Design.-Immunohistochemical staining with anti-JL1 and other commonly used markers for LC was performed on paraffin-embedded skin biopsies from 32 cases of LC with acute lymphoblastic leukemia/lymphoma and acute myelogenous leukemia. Immunohistochemical staining score was evaluated in each case according to the proportion of positive tumor cells found. JL1 staining was also done on 96 reactive or neoplastic cutaneous lesions. Results.-JL1 was detected in 7 of 11 acute lymphoblastic leukemia/lymphoma LC (63.6%) and 7 of 21 acute myelogenous leukemia LC (33.3%), with invariably highstaining scores. None of the other cutaneous lesions or normal tissues expressed JL1. The expression pattern of JL1 was not altered in 2 patients with follow-up biopsies. Conclusions.-Our finding that JL1 is expressed exclusively and stably by leukemic cells suggests that it can be used as a useful adjunctive marker for initial diagnosis and follow-up biopsy of LC, particularly in cases of scarce infiltrates.

Original languageEnglish
Pages (from-to)95-102
Number of pages8
JournalArchives of Pathology and Laboratory Medicine
Volume134
Issue number1
StatePublished - 1 Jan 2010

Fingerprint

Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Skin
Staining and Labeling
Biopsy
Skin Diseases
Acute Myeloid Leukemia
Thymocytes
Surface Antigens
Paraffin
Differential Diagnosis
Bone Marrow
Neoplasms

Cite this

Park, Y. S., Park., S. H., Park., S. J., Kim., Y., Jang., K. T., Ko., Y. H., ... Park., C. S. (2010). Expression of JL1 Is an effective adjunctive marker of leukemia cutis. Archives of Pathology and Laboratory Medicine, 134(1), 95-102.
Park, Young Su ; Park., So Hyung ; Park., Seo Jeong ; Kim., Youngji ; Jang., Kee Taek ; Ko., Young Hyeh ; Lee., Mi Woo ; Huh., Joo Ryung ; Park., Chan Sik. / Expression of JL1 Is an effective adjunctive marker of leukemia cutis. In: Archives of Pathology and Laboratory Medicine. 2010 ; Vol. 134, No. 1. pp. 95-102.
@article{ce99547d3617402a9caea3b6d15ffebe,
title = "Expression of JL1 Is an effective adjunctive marker of leukemia cutis",
abstract = "Context.-Specific differentiation of leukemia cutis (LC) from nonleukemic dermatoses is crucial to ensure proper treatment for the disease. Because of the exceptionally variable histologic features of LC and the frequent nonleukemic dermatoses in leukemia patients, identification of leukemic cells that infiltrate skin lesions is important. Here, we introduce JL1, a novel leukemiaassociated surface antigen, which is not expressed in mature human tissue but in cortical thymocytes and small subpopulations of bone marrow hematopoietic precursors. Objectives.-To assess the expression pattern of JL1 in LC and compare it with other commonly used markers. Also, to evaluate the expression of JL1 in other cutaneous lesions that need differential diagnoses. Design.-Immunohistochemical staining with anti-JL1 and other commonly used markers for LC was performed on paraffin-embedded skin biopsies from 32 cases of LC with acute lymphoblastic leukemia/lymphoma and acute myelogenous leukemia. Immunohistochemical staining score was evaluated in each case according to the proportion of positive tumor cells found. JL1 staining was also done on 96 reactive or neoplastic cutaneous lesions. Results.-JL1 was detected in 7 of 11 acute lymphoblastic leukemia/lymphoma LC (63.6{\%}) and 7 of 21 acute myelogenous leukemia LC (33.3{\%}), with invariably highstaining scores. None of the other cutaneous lesions or normal tissues expressed JL1. The expression pattern of JL1 was not altered in 2 patients with follow-up biopsies. Conclusions.-Our finding that JL1 is expressed exclusively and stably by leukemic cells suggests that it can be used as a useful adjunctive marker for initial diagnosis and follow-up biopsy of LC, particularly in cases of scarce infiltrates.",
author = "Park, {Young Su} and Park., {So Hyung} and Park., {Seo Jeong} and Youngji Kim. and Jang., {Kee Taek} and Ko., {Young Hyeh} and Lee., {Mi Woo} and Huh., {Joo Ryung} and Park., {Chan Sik}",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "134",
pages = "95--102",
journal = "Archives of Pathology and Laboratory Medicine",
issn = "0003-9985",
publisher = "College of American Pathologists",
number = "1",

}

Park, YS, Park., SH, Park., SJ, Kim., Y, Jang., KT, Ko., YH, Lee., MW, Huh., JR & Park., CS 2010, 'Expression of JL1 Is an effective adjunctive marker of leukemia cutis', Archives of Pathology and Laboratory Medicine, vol. 134, no. 1, pp. 95-102.

Expression of JL1 Is an effective adjunctive marker of leukemia cutis. / Park, Young Su; Park., So Hyung; Park., Seo Jeong; Kim., Youngji; Jang., Kee Taek; Ko., Young Hyeh; Lee., Mi Woo; Huh., Joo Ryung; Park., Chan Sik.

In: Archives of Pathology and Laboratory Medicine, Vol. 134, No. 1, 01.01.2010, p. 95-102.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of JL1 Is an effective adjunctive marker of leukemia cutis

AU - Park, Young Su

AU - Park., So Hyung

AU - Park., Seo Jeong

AU - Kim., Youngji

AU - Jang., Kee Taek

AU - Ko., Young Hyeh

AU - Lee., Mi Woo

AU - Huh., Joo Ryung

AU - Park., Chan Sik

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Context.-Specific differentiation of leukemia cutis (LC) from nonleukemic dermatoses is crucial to ensure proper treatment for the disease. Because of the exceptionally variable histologic features of LC and the frequent nonleukemic dermatoses in leukemia patients, identification of leukemic cells that infiltrate skin lesions is important. Here, we introduce JL1, a novel leukemiaassociated surface antigen, which is not expressed in mature human tissue but in cortical thymocytes and small subpopulations of bone marrow hematopoietic precursors. Objectives.-To assess the expression pattern of JL1 in LC and compare it with other commonly used markers. Also, to evaluate the expression of JL1 in other cutaneous lesions that need differential diagnoses. Design.-Immunohistochemical staining with anti-JL1 and other commonly used markers for LC was performed on paraffin-embedded skin biopsies from 32 cases of LC with acute lymphoblastic leukemia/lymphoma and acute myelogenous leukemia. Immunohistochemical staining score was evaluated in each case according to the proportion of positive tumor cells found. JL1 staining was also done on 96 reactive or neoplastic cutaneous lesions. Results.-JL1 was detected in 7 of 11 acute lymphoblastic leukemia/lymphoma LC (63.6%) and 7 of 21 acute myelogenous leukemia LC (33.3%), with invariably highstaining scores. None of the other cutaneous lesions or normal tissues expressed JL1. The expression pattern of JL1 was not altered in 2 patients with follow-up biopsies. Conclusions.-Our finding that JL1 is expressed exclusively and stably by leukemic cells suggests that it can be used as a useful adjunctive marker for initial diagnosis and follow-up biopsy of LC, particularly in cases of scarce infiltrates.

AB - Context.-Specific differentiation of leukemia cutis (LC) from nonleukemic dermatoses is crucial to ensure proper treatment for the disease. Because of the exceptionally variable histologic features of LC and the frequent nonleukemic dermatoses in leukemia patients, identification of leukemic cells that infiltrate skin lesions is important. Here, we introduce JL1, a novel leukemiaassociated surface antigen, which is not expressed in mature human tissue but in cortical thymocytes and small subpopulations of bone marrow hematopoietic precursors. Objectives.-To assess the expression pattern of JL1 in LC and compare it with other commonly used markers. Also, to evaluate the expression of JL1 in other cutaneous lesions that need differential diagnoses. Design.-Immunohistochemical staining with anti-JL1 and other commonly used markers for LC was performed on paraffin-embedded skin biopsies from 32 cases of LC with acute lymphoblastic leukemia/lymphoma and acute myelogenous leukemia. Immunohistochemical staining score was evaluated in each case according to the proportion of positive tumor cells found. JL1 staining was also done on 96 reactive or neoplastic cutaneous lesions. Results.-JL1 was detected in 7 of 11 acute lymphoblastic leukemia/lymphoma LC (63.6%) and 7 of 21 acute myelogenous leukemia LC (33.3%), with invariably highstaining scores. None of the other cutaneous lesions or normal tissues expressed JL1. The expression pattern of JL1 was not altered in 2 patients with follow-up biopsies. Conclusions.-Our finding that JL1 is expressed exclusively and stably by leukemic cells suggests that it can be used as a useful adjunctive marker for initial diagnosis and follow-up biopsy of LC, particularly in cases of scarce infiltrates.

UR - http://www.scopus.com/inward/record.url?scp=75149113642&partnerID=8YFLogxK

M3 - Article

C2 - 20073611

AN - SCOPUS:75149113642

VL - 134

SP - 95

EP - 102

JO - Archives of Pathology and Laboratory Medicine

JF - Archives of Pathology and Laboratory Medicine

SN - 0003-9985

IS - 1

ER -

Park YS, Park. SH, Park. SJ, Kim. Y, Jang. KT, Ko. YH et al. Expression of JL1 Is an effective adjunctive marker of leukemia cutis. Archives of Pathology and Laboratory Medicine. 2010 Jan 1;134(1):95-102.